Design Therapeutics, Inc. Operating Lease Liability
Design Therapeutics, Inc. (DSGN) had Operating Lease Liability of $2.66 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-03
- 2026-06-30: Operating Lease, Liability $2.66M.
- 2026-03-31: Operating Lease, Liability $2.73M.
- 2025-12-31: Operating Lease, Liability $1.53M.
- 2025-09-30: Operating Lease, Liability $1.74M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $2.66M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $2.73M 10-Q · filed 2026-04-28 |
| 2025-12-31 | $1.53M 10-K · filed 2026-03-09 |
| 2025-09-30 | $1.74M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $1.95M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $2.14M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $2.33M 10-K · filed 2025-03-10 |
| 2024-09-30 | $2.52M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $2.70M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $2.88M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $3.05M 10-K · filed 2024-03-19 |
| 2023-09-30 | $3.22M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $3.38M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $3.54M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $3.69M 10-K · filed 2023-03-14 |
| 2022-09-30 | $3.84M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $3.98M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $3.52M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $3.63M 10-K · filed 2022-03-10 |
| 2021-09-30 | $3.75M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |